BioNTech (NASDAQ:BNTX) Price Target Lowered to $145.00 at HC Wainwright

BioNTech (NASDAQ:BNTX) had its target price cut by HC Wainwright from $150.00 to $145.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 55.38% from the stock’s current price.

A number of other analysts also recently weighed in on the company. Citigroup began coverage on BioNTech in a research note on Thursday, March 13th. They issued a “buy” rating and a $145.00 price target on the stock. Wells Fargo & Company began coverage on shares of BioNTech in a research note on Wednesday, December 11th. They set an “overweight” rating and a $170.00 price target on the stock. Morgan Stanley cut their price target on shares of BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a report on Tuesday, March 11th. BMO Capital Markets boosted their price objective on shares of BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a report on Tuesday, March 11th. Finally, Truist Financial began coverage on shares of BioNTech in a report on Friday, January 10th. They issued a “buy” rating and a $172.00 target price for the company. Three research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $143.44.

BioNTech Price Performance

Shares of NASDAQ BNTX opened at $93.32 on Tuesday. The stock has a fifty day moving average price of $110.02 and a 200 day moving average price of $113.27. BioNTech has a 1-year low of $76.53 and a 1-year high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The company has a market cap of $22.39 billion, a PE ratio of -44.44 and a beta of 0.30.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping the consensus estimate of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.24 billion. During the same quarter last year, the business earned $1.90 EPS. The business’s revenue was down 19.5% on a year-over-year basis. Sell-side analysts forecast that BioNTech will post -3.88 EPS for the current year.

Hedge Funds Weigh In On BioNTech

A number of hedge funds have recently made changes to their positions in BNTX. Jones Financial Companies Lllp increased its holdings in shares of BioNTech by 110.3% during the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock worth $53,000 after buying an additional 246 shares during the last quarter. Quintet Private Bank Europe S.A. increased its stake in BioNTech by 823.5% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock worth $88,000 after acquiring an additional 700 shares during the last quarter. Allianz SE purchased a new position in shares of BioNTech in the 4th quarter worth about $90,000. GAMMA Investing LLC lifted its stake in shares of BioNTech by 48.2% in the 4th quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock valued at $105,000 after purchasing an additional 300 shares in the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. purchased a new stake in shares of BioNTech during the 4th quarter worth about $137,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.